Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that FOLR1 positive status confers therapeutic sensitivity to Mirvetuximab soravtansine in patients with High-Grade Serous Fallopian Tube Cancer.
This statement is based on a regulatory approval from the European Medicines Agency:
ELAHERE as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FDalpha) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.